Connect your AI

Kura Oncology KURA Operating Cash Flow

Operating Cash Flow at other companies

Johnson & JohnsonJNJ

$2.51B-39.8%

AmgenAMGN

$2.19B+57.4%

ExelixisEXEL

$251.85M+19.1%

Syndax PharmaceuticalsSNDX

-$50.35M+47.1%

AbbVieABBV

$3.83B+134%

Corvus PharmaceuticalsCRVS

-$10.37M-25.5%

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$942.78M+86.2%

Enterprise value$927.97M+95.5%

P/S13.2×+3.9×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's operating cash flow?: Kura Oncology (KURA) reported operating cash flow of -$85.85M in Q1 2026.
How has Kura Oncology's operating cash flow changed year-over-year?: Kura Oncology's operating cash flow decreased by 19.4% year-over-year, from -$71.93M to -$85.85M.
What is the long-term trend for Kura Oncology's operating cash flow?: Over 3 years (2021 to 2024), Kura Oncology's operating cash flow has grown at a 8.7% compound annual growth rate (CAGR), from -$104.55M to $134.32M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.